We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

This study is currently recruiting participants.
Verified November 2017 by National Cancer Institute (NCI)
Sponsor:
ClinicalTrials.gov Identifier:
NCT02180867
First Posted: July 3, 2014
Last Update Posted: November 21, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
National Cancer Institute (NCI)
  Purpose
This randomized phase II/III trial studies how well pazopanib hydrochloride, combination chemotherapy, and radiation therapy work and compares it to radiation therapy alone or in combination with pazopanib hydrochloride or combination chemotherapy in treating patients with newly diagnosed non-rhabdomyosarcoma soft tissue sarcomas that can be removed by surgery. Radiation therapy uses high energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as ifosfamide and doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether radiation therapy works better when given with or without combination chemotherapy and/or pazopanib hydrochloride in treating patients with non-rhabdomyosarcoma soft tissue sarcomas.

Condition Intervention Phase
Adult Fibrosarcoma Alveolar Soft Part Sarcoma Angiomatoid Fibrous Histiocytoma Atypical Fibroxanthoma Clear Cell Sarcoma of Soft Tissue Epithelioid Malignant Peripheral Nerve Sheath Tumor Epithelioid Sarcoma Extraskeletal Myxoid Chondrosarcoma Extraskeletal Osteosarcoma Fibrohistiocytic Neoplasm Glomus Tumor of the Skin Inflammatory Myofibroblastic Tumor Intimal Sarcoma Leiomyosarcoma Liposarcoma Low Grade Fibromyxoid Sarcoma Low Grade Myofibroblastic Sarcoma Malignant Cutaneous Granular Cell Tumor Malignant Peripheral Nerve Sheath Tumor Malignant Triton Tumor Mesenchymal Chondrosarcoma Myxofibrosarcoma Myxoid Chondrosarcoma Myxoinflammatory Fibroblastic Sarcoma Nerve Sheath Neoplasm PEComa Pericytic Neoplasm Plexiform Fibrohistiocytic Tumor Sclerosing Epithelioid Fibrosarcoma Stage IB Soft Tissue Sarcoma AJCC v7 Stage IIB Soft Tissue Sarcoma AJCC v7 Stage III Soft Tissue Sarcoma AJCC v7 Stage IV Soft Tissue Sarcoma AJCC v7 Synovial Sarcoma Undifferentiated (Embryonal) Sarcoma Undifferentiated High Grade Pleomorphic Sarcoma of Bone Drug: Doxorubicin Hydrochloride Drug: Ifosfamide Other: Laboratory Biomarker Analysis Drug: Pazopanib Hydrochloride Other: Pharmacological Study Radiation: Radiation Therapy Procedure: Therapeutic Conventional Surgery Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Event-free survival (EFS) (Phase III) [ Time Frame: Time to the first occurrence of progression, relapse after response, secondary cancer or death from any cause, assessed up to 60 months ]
    The null (radiation therapy only) 5-year EFS for patients with localized unresectable chemo-resistant tumors is expected to be about 30%.

  • Potential benefit for chemoradiotherapy plus pazopanib hydrochloride defined as protocol week 13 pathologic response (Phase II) [ Time Frame: Week 13 ]
    The expected null (chemotherapy only) pathologic response rate (90%+ necrosis at week 13) is 40%.

  • Potential benefit for radiotherapy plus pazopanib hydrochloride defined as protocol week 10 pathologic response (Phase II/III) [ Time Frame: Week 10 ]
    The expected null (radiation therapy only) pathologic response rate (90%+ necrosis at Week 10) is 10%.


Secondary Outcome Measures:
  • Adverse event profile of the treatments delivered (chemo-radiotherapy; radiotherapy) [ Time Frame: Up to 60 months ]
    Will be characterized using the current Common Terminology Criteria for Adverse Events version.

  • Distant failure defined as disease recurrence at sites other than the primary site and diagnosis and nodes regional to that site (metastatic disease, whether or not present at diagnosis), with or without loco-regional failure [ Time Frame: Up to 60 months ]
    The relative risk of specific failure types will be estimated and compared descriptively using the Cox proportional hazard model.

  • Local failure defined as disease recurrence only at the primary site of disease at diagnosis [ Time Frame: Up to 60 months ]
    The relative risk of specific failure types will be estimated and compared descriptively using the Cox proportional hazard model.

  • Regional failure defined as disease recurrence at lymph nodes regional to the primary disease site, with or without local failure but without distant failure [ Time Frame: Up to 60 months ]
    The relative risk of specific failure types will be estimated and compared descriptively using the Cox proportional hazard model.


Other Outcome Measures:
  • Change in fludeoxyglucose F 18 (FDG) positron emission tomography (PET) maximum standard uptake value (SUVmax) [ Time Frame: Baseline to week 13 ]
    The FDG-PET images will be assessed as positive or negative at the primary site and PET response will be descriptively compared to the findings at Week 10 or 13 surgery.

  • Circulating Tumor deoxyribonucleic acid (DNA) [ Time Frame: Up to 60 months ]
    Descriptive analyses will be performed.

  • Frequency with which combinations of actionable mutations are observed in individual tumor types [ Time Frame: Up to 60 months ]
    Descriptive statistical analyses will be estimated.

  • Pharmacokinetic parameters of doxorubicin hydrochloride and pazopanib hydrochloride [ Time Frame: Up to 48 hours after the end of infusion ]
    The present trial is designed to allow detection of statistically significant changes in the mean clearance of doxorubicin of at least 25% using a one-sample analysis, which concerns testing an observed experimental mean against the expected (historical) mean of 25.6 L/h/m^2.

  • Rates of actionable mutations on whole genome sequencing [ Time Frame: Up to 60 months ]
    Descriptive and exploratory statistical analyses will be carried out.

  • Relative risk of failure based on both standard imaging and pathologic assessment [ Time Frame: Up to 60 months ]
    Log-rank test will be used to see if one response assessment method produces a larger difference in outcome between the response categories.

  • The relative frequency of actionable mutations across the whole cohort and within more common histological subtypes, like synovial sarcoma and malignant peripheral nerve sheath tumors [ Time Frame: Up to 60 months ]
    Descriptive statistical analyses will be estimated.


Estimated Enrollment: 340
Actual Study Start Date: July 11, 2014
Estimated Primary Completion Date: June 13, 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Regimen A (pazopanib hydrochloride, chemoradiation)
See Regimen A Detailed Description.
Drug: Doxorubicin Hydrochloride
Given IV
Other Names:
  • 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI)
  • ADM
  • Adriacin
  • Adriamycin
  • Adriamycin hydrochloride
  • Adriamycin PFS
  • Adriamycin RDF
  • ADRIAMYCIN, HYDROCHLORIDE
  • Adriamycine
  • Adriblastina
  • Adriblastine
  • Adrimedac
  • Chloridrato de Doxorrubicina
  • DOX
  • DOXO-CELL
  • Doxolem
  • Doxorubicin.HCl
  • Doxorubin
  • Farmiblastina
  • FI 106
  • FI-106
  • hydroxydaunorubicin
  • Rubex
Drug: Ifosfamide
Given IV
Other Names:
  • Asta Z 4942
  • Asta Z-4942
  • Cyfos
  • Holoxan
  • Holoxane
  • Ifex
  • IFO
  • IFO-Cell
  • Ifolem
  • Ifomida
  • Ifomide
  • Ifosfamidum
  • Ifoxan
  • IFX
  • Iphosphamid
  • Iphosphamide
  • Iso-Endoxan
  • Isoendoxan
  • Isophosphamide
  • Mitoxana
  • MJF 9325
  • MJF-9325
  • Naxamide
  • Seromida
  • Tronoxal
  • Z 4942
  • Z-4942
Other: Laboratory Biomarker Analysis
Correlative studies
Drug: Pazopanib Hydrochloride
Given PO
Other Names:
  • GW786034B
  • Votrient
Other: Pharmacological Study
Correlative studies
Radiation: Radiation Therapy
Undergo radiation therapy
Other Names:
  • Cancer Radiotherapy
  • Irradiate
  • Irradiated
  • irradiation
  • Radiation
  • Radiotherapeutics
  • Radiotherapy
  • RT
  • Therapy, Radiation
Procedure: Therapeutic Conventional Surgery
Undergo surgery
Experimental: Regimen B (chemoradiation)
See Regimen B Detailed Description.
Drug: Doxorubicin Hydrochloride
Given IV
Other Names:
  • 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI)
  • ADM
  • Adriacin
  • Adriamycin
  • Adriamycin hydrochloride
  • Adriamycin PFS
  • Adriamycin RDF
  • ADRIAMYCIN, HYDROCHLORIDE
  • Adriamycine
  • Adriblastina
  • Adriblastine
  • Adrimedac
  • Chloridrato de Doxorrubicina
  • DOX
  • DOXO-CELL
  • Doxolem
  • Doxorubicin.HCl
  • Doxorubin
  • Farmiblastina
  • FI 106
  • FI-106
  • hydroxydaunorubicin
  • Rubex
Drug: Ifosfamide
Given IV
Other Names:
  • Asta Z 4942
  • Asta Z-4942
  • Cyfos
  • Holoxan
  • Holoxane
  • Ifex
  • IFO
  • IFO-Cell
  • Ifolem
  • Ifomida
  • Ifomide
  • Ifosfamidum
  • Ifoxan
  • IFX
  • Iphosphamid
  • Iphosphamide
  • Iso-Endoxan
  • Isoendoxan
  • Isophosphamide
  • Mitoxana
  • MJF 9325
  • MJF-9325
  • Naxamide
  • Seromida
  • Tronoxal
  • Z 4942
  • Z-4942
Other: Laboratory Biomarker Analysis
Correlative studies
Other: Pharmacological Study
Correlative studies
Radiation: Radiation Therapy
Undergo radiation therapy
Other Names:
  • Cancer Radiotherapy
  • Irradiate
  • Irradiated
  • irradiation
  • Radiation
  • Radiotherapeutics
  • Radiotherapy
  • RT
  • Therapy, Radiation
Procedure: Therapeutic Conventional Surgery
Undergo surgery
Experimental: Regimen C (pazopanib hydrochloride, radiation therapy)

INDUCTION PHASE: Patients receive pazopanib hydrochloride PO QD on weeks 1-9. Patients undergo radiation therapy on weeks 1-7.

SURGERY: Patients undergo surgery on week 10.

CONTINUATION PHASE: Patients receive pazopanib hydrochloride PO QD on weeks 13-25. Patients undergo radiation therapy on weeks 13-16 for a total of 50 Gy. Patients with impaired wound healing within 8 weeks of the date of surgery, are removed from protocol therapy effective the date 8 weeks after week 10 surgery.

Other: Laboratory Biomarker Analysis
Correlative studies
Drug: Pazopanib Hydrochloride
Given PO
Other Names:
  • GW786034B
  • Votrient
Other: Pharmacological Study
Correlative studies
Radiation: Radiation Therapy
Undergo radiation therapy
Other Names:
  • Cancer Radiotherapy
  • Irradiate
  • Irradiated
  • irradiation
  • Radiation
  • Radiotherapeutics
  • Radiotherapy
  • RT
  • Therapy, Radiation
Procedure: Therapeutic Conventional Surgery
Undergo surgery
Experimental: Regimen D (radiation therapy)

INDUCTION PHASE: Patients undergo radiation therapy on weeks 1-7.

SURGERY: Patients undergo surgery on week 10.

CONTINUATION PHASE: Patients undergo radiation therapy on weeks 13-16 for a total of 50 Gy. Patients with impaired wound healing within 8 weeks of the date of surgery, are removed from protocol therapy effective the date 8 weeks after week 10 surgery.

Other: Laboratory Biomarker Analysis
Correlative studies
Other: Pharmacological Study
Correlative studies
Radiation: Radiation Therapy
Undergo radiation therapy
Other Names:
  • Cancer Radiotherapy
  • Irradiate
  • Irradiated
  • irradiation
  • Radiation
  • Radiotherapeutics
  • Radiotherapy
  • RT
  • Therapy, Radiation
Procedure: Therapeutic Conventional Surgery
Undergo surgery

  Hide Detailed Description

Detailed Description:

PRIMARY OBJECTIVES:

I. To identify the dose of pazopanib hydrochloride (pazopanib) that is feasible when given in combination with radiation or chemoradiation in pediatric and adult patients newly diagnosed with unresected intermediate- and high-risk non-rhabdomyosarcoma soft tissue sarcomas (NRSTS).

II. To compare the rates of near complete pathologic response (> 90% necrosis) with the addition of pazopanib to preoperative chemoradiation versus preoperative chemoradiation alone for potentially resectable > 5 cm, grade 3 intermediate to high risk chemotherapy-sensitive NRSTS in the phase II portion of the study for this cohort.

III. To compare the rates of near complete pathologic response (> 90% necrosis) with the addition of pazopanib to preoperative radiotherapy versus preoperative radiotherapy alone for potentially resectable intermediate to high risk adult and pediatric NRSTS in the phase II portion of the study for this cohort (using a phase II decision rule to go onto the phase III portion of the study).

IV. To compare the rates of event-free survival (EFS) with the addition of pazopanib to preoperative radiotherapy versus preoperative radiotherapy alone for localized intermediate to high risk adult and pediatric NRSTS in the phase III portion of the study for this cohort if the phase II decision rule is passed.

SECONDARY OBJECTIVES:

I. To estimate the rates of local failure, regional failure, distant metastasis free survival, disease-free survival, and overall survival with the addition of pazopanib to preoperative chemoradiation or preoperative radiation in intermediate to high risk adult and pediatric NRSTS.

II. To compare the pattern of recurrence (local, regional and distant) between preoperative chemoradiation or radiation with the addition of pazopanib for adult and pediatric NRSTS.

III. To define the toxicities of ifosfamide and doxorubicin hydrochloride (doxorubicin) chemotherapy and radiation when used in combination with pazopanib in intermediate to high risk adult and pediatric NRSTS.

IV. To define the toxicities of preoperative radiotherapy when used in combination with pazopanib in intermediate to high risk adult and pediatric NRSTS.

TERTIARY OBJECTIVES:

I. To gain insight into the disease biology of childhood and adult NRSTS through analysis of actionable mutations and whole genome sequencing.

II. To determine if microvessel density and circulating tumor deoxyribonucleic acid (DNA) predict response to pazopanib and outcome.

III. To determine the effect of pazopanib on doxorubicin exposure in children and adults with NRSTS.

IV. To evaluate change in fludeoxyglucose F 18 (FDG) positron emission tomography (PET) maximum standard uptake value (SUVmax) from baseline to week 10 or 13 in patients with unresected tumors and to correlate this change with pathologic response and EFS.

V. To compare the rate of response by standard imaging and pathologic assessment to determine which correlates better with local tumor control, distant tumor control, EFS, and overall survival.

OUTLINE: This is a dose-escalation study of pazopanib hydrochloride.

CHEMOTHERAPY COHORT: Patients eligible for chemotherapy cohort are randomized to 1 of 2 treatment regimens.

REGIMEN A:

INDUCTION PHASE: Patients receive pazopanib hydrochloride orally (PO) once daily (QD) on weeks 1-12, ifosfamide intravenously (IV) over 2-4 hours on days 1-3 on weeks 1, 4, 7, 10, and doxorubicin hydrochloride IV over 1-15 minutes on days 1-2 on weeks 1 and 4. At least 24 hours after the completion of week 4 doxorubicin hydrochloride, patients undergo radiation therapy on weeks 4-10.

SURGERY: Patients undergo surgery on week 13.

CONTINUATION PHASE: Patients receive pazopanib hydrochloride PO QD on weeks 16-25, ifosfamide IV over 2-4 hours on days 1-3 on weeks 16 and 19, and doxorubicin hydrochloride IV over 1-15 minutes on days 1-2 on weeks 16, 19, and 22. At least 24 hours after the completion of doxorubicin hydrochloride, if required, patients undergo radiation therapy on weeks 16-25 for a total of 45 Gy. Patients with impaired wound healing within 6 weeks of the date of surgery, have week 16 chemotherapy postponed until radiation therapy (if needed) begins. Patients with impaired wound healing within 8 weeks of the date of surgery, are removed from protocol therapy effective the date 8 weeks after week 13 surgery.

REGIMEN B:

INDUCTION PHASE: Patients receive ifosfamide IV over 2-4 hours on days 1-3 on weeks 1, 4, 7, 10 and doxorubicin hydrochloride IV over 1-15 minutes on days 1-2 on weeks 1 and 4. At least 24 hours after the completion of week 4 doxorubicin hydrochloride, patients undergo radiation therapy on weeks 4-10.

SURGERY: Patients undergo surgery on week 13.

CONTINUATION PHASE: Patients receive ifosfamide IV over 2-4 hours on days 1-3 on weeks 16 and 19 and doxorubicin hydrochloride IV over 1-15 minutes on days 1-2 on weeks 16, 19, and 22. At least 24 hours after the completion of doxorubicin hydrochloride, if required, patients undergo radiation therapy on weeks 16-25 for a total of 45 Gy. Patients with impaired wound healing within 6 weeks of the date of surgery, have week 16 chemotherapy postponed until radiation therapy (if needed) begins. Patients with impaired wound healing within 8 weeks of the date of surgery, are removed from protocol therapy effective the date 8 weeks after week 13 surgery.

NON-CHEMOTHERAPY COHORT: Patients eligible for non-chemotherapy cohort are randomized to 1 of 2 treatment regimens.

REGIMEN C:

INDUCTION PHASE: Patients receive pazopanib hydrochloride PO QD on weeks 1-9. Patients undergo radiation therapy on weeks 1-7.

SURGERY: Patients undergo surgery on week 10.

CONTINUATION PHASE: Patients receive pazopanib hydrochloride PO QD on weeks 13-25. Patients undergo radiation therapy on weeks 13-16 for a total of 50 Gy. Patients with impaired wound healing within 8 weeks of the date of surgery, are removed from protocol therapy effective the date 8 weeks after week 10 surgery.

REGIMEN D:

INDUCTION PHASE: Patients undergo radiation therapy on weeks 1-7.

SURGERY: Patients undergo surgery on week 10.

CONTINUATION PHASE: Patients undergo radiation therapy on weeks 13-16 for a total of 50 Gy. Patients with impaired wound healing within 8 weeks of the date of surgery, are removed from protocol therapy effective the date 8 weeks after week 10 surgery.

After completion of study treatment, patients are followed up at 6, 12, 18, 24, 30, 36, 48, and 60 months.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   2 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Newly diagnosed and histopathologically confirmed, potentially resectable NRSTS of the extremity and trunk will be eligible for the chemotherapy or non-chemotherapy cohort based on:

    • Evidence of chemotherapy sensitivity of the histologic sarcoma subtype based on existing evidence from prior clinical trials
    • Sufficient risk of metastatic disease to warrant chemotherapy based on size and grade and
    • Medically deemed able or unable to undergo chemotherapy
    • Notes: an incisional biopsy or core biopsy is preferred; fine needle aspiration biopsy is not acceptable to establish the diagnosis
  • ELIGIBLE SITES:

    • Extremities: upper (including shoulder) and lower (including hip)
    • Trunk: body wall
  • INELIGIBLE SITES: Head and neck, visceral organs (with the exception of embryonal sarcoma of the liver), retroperitoneum, peritoneum, pelvis within the confines of the bony pelvis
  • ELIGIBILITY FOR CHEMOTHERAPY COHORT:
  • Stage T2a/b (> 5 cm) and grade 2 or 3 AND
  • One of the following chemosensitive histologies as defined in the World Health Organization (WHO) classification of soft tissue tumors (with some evidence of good response to chemoradiation and of sufficient high risk of metastases, or clear evidence of metastases):

    • Unclassified soft tissue sarcomas that are too undifferentiated to be placed in a specific pathologic category in the WHO classification (often called "undifferentiated soft tissue sarcoma" or "soft tissue sarcoma not otherwise specified [NOS]")
    • Synovial sarcoma
    • Angiosarcoma of soft tissue
    • Adult fibrosarcoma
    • Mesenchymal (extraskeletal) chondrosarcoma
    • Leiomyosarcoma
    • Liposarcoma (excluding myxoid liposarcoma)
    • Undifferentiated pleomorphic sarcoma
    • Embryonal sarcoma of the liver
  • Patients meeting the above criteria (histology, size, and grade) with the EXCEPTION of histologies noted above may enroll on the chemotherapy cohort or the non-chemotherapy cohort at the discretion of the enrolling investigator; patients meeting these criteria with the EXCEPTION of histologies noted above but medically deemed unable to receive chemotherapy or who elect not to receive chemotherapy are eligible for the non-chemotherapy cohort
  • Patients with the following histologies are only eligible for the chemotherapy cohort and cannot enroll on the non-chemotherapy cohort:

    • Unclassified soft tissue sarcomas that are too undifferentiated to be placed in a specific pathologic category in the WHO classification (often called "undifferentiated soft tissue sarcoma" or "soft tissue sarcoma NOS") in patients < 30 years of age
    • Synovial sarcoma
    • Embryonal sarcoma of the liver
  • ELIGIBILITY FOR NON-CHEMOTHERAPY COHORT:
  • Patients with any size of grade 2 or 3 of the following "intermediate (rarely metastasizing)" or "malignant" tumors, as defined in the WHO classification of soft tissue tumors for which we have consensus data of chemotherapy-resistance are eligible only for the non-chemotherapy cohort:

    • So-called fibrohistiocytic tumors - plexiform fibrohistiocytic tumor, giant cell tumor of soft tissues
    • Fibroblastic/myofibroblastic tumors - solitary fibrous tumor, malignant solitary fibrous tumor, inflammatory myofibroblastic tumor, low grade myofibroblastic sarcoma, myxoinflammatory fibroblastic sarcoma, atypical myxoinflammatory fibroblastic tumor, myxofibrosarcoma, low grade fibromyxoid sarcoma, sclerosing epithelioid fibrosarcoma
    • Tumors of uncertain differentiation - epithelioid sarcoma, alveolar soft part sarcoma, clear cell sarcoma of soft tissue, angiomatoid fibrous histiocytoma, ossifying fibromyxoid tumor, myoepithelioma, myoepithelial carcinoma, extraskeletal myxoid chondrosarcoma, neoplasms with perivascular epithelioid cell differentiation (PEComa), intimal sarcoma, atypical fibroxanthoma, mixed tumor NOS, phosphaturic mesenchymal tumor, malignant ossifying fibromyxoid tumor, malignant mixed tumor, malignant phosphaturic mesenchymal tumor
    • Chondro-osseous tumors - extraskeletal osteosarcoma
    • Pericytic (perivascular) tumors - malignant glomus tumor
    • Nerve sheath tumors - malignant peripheral nerve sheath tumor, malignant granular cell tumor, epithelioid malignant peripheral nerve sheath tumor, malignant Triton tumor
    • Undifferentiated sarcomas (with a specific pathologic category in the WHO classification) - undifferentiated round cell sarcoma, undifferentiated epithelioid sarcoma, undifferentiated spindle cell sarcoma
  • Patients meeting the criteria (histology, size, and grade) with the EXCEPTION of histologies noted above may enroll on the non-chemotherapy cohort at the discretion of the enrolling investigator; patients meeting these criteria with the EXCEPTION of histologies noted above but medically deemed unable to receive chemotherapy or who elect not to receive chemotherapy are eligible for the non-chemotherapy cohort; note that tumors arising in bone are NOT eligible for this study
  • Extent of disease:

    • Patients with non-metastatic and metastatic disease are eligible
    • Initially unresectable patients, with or without metastatic disease, are eligible as long as there is a commitment at enrollment to resect the primary tumor
  • Sufficient tissue and blood must be available to submit for required biology studies
  • Lansky performance status score >= 70 for patients =< 16 years of age
  • Karnofsky performance status score >= 70 for patients > 16 years of age
  • Absolute neutrophil count >= 1500/uL; Note: no transfusions are permitted 7 days prior to laboratory studies to determine eligibility
  • Platelet count >= 100,000/uL; Note: no transfusions are permitted 7 days prior to laboratory studies to determine eligibility
  • Hemoglobin >= 8 g/dL for patients =< 16 years of age; >= 9 g/dL for patients > 16 years of age; Note: no transfusions are permitted 7 days prior to laboratory studies to determine eligibility
  • Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 or normal serum creatinine based on age/gender as follows:

    • 2 to < 6 years; 0.8 mg/dL male; 0.8 mg/dL female
    • 6 to < 10 years; 1 mg/dL male; 1 mg/dL female
    • 10 to < 13 years; 1.2 mg/dL male; 1.2 mg/dL female
    • 13 to < 16 years; 1.5 mg/dL male; 1.4 mg/dL female
    • >= 16 years; 1.5 mg/dL male; 1.4 mg/dL female
  • Total bilirubin =< 1.5 x upper limit of normal (ULN) for age
  • Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) or serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) < 2.5 x upper limit of normal (ULN) for age
  • Shortening fraction of >= 27% by echocardiogram OR ejection fraction of >= 50% by radionuclide angiogram
  • Corrected QT interval (QTc) < 480 msec
  • No evidence of dyspnea at rest, no exercise intolerance, and a resting pulse oximetry reading > 94% on room air if there is clinical indication for determination
  • Patients on low molecular weight heparin or Coumadin (with a stable international normalized ratio [INR]) are eligible
  • Patient must have a life expectancy of at least 3 months with appropriate therapy
  • All patients and/or their parents or legal guardians must sign a written informed consent
  • All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met

Exclusion Criteria:

  • Patients with grade 1 NRSTS tumors of any size are not eligible
  • Patients with known central nervous system (CNS) metastases are not eligible; Note: brain imaging is not an eligibility requirement
  • Patients with evidence of active bleeding or bleeding diathesis will be excluded (Note: patients aged > 17 years with excess of 2.5 mL of hemoptysis are not eligible)
  • Patients with gross total resection of the primary tumor prior to enrollment on ARST1321 are NOT eligible; patients who have experienced tumor recurrence after a gross total tumor resection are NOT eligible
  • Patients with uncontrolled hypertension are ineligible; uncontrolled hypertension is defined as follows:

    • Patients aged =< 17 years: greater than 95th percentile systolic and diastolic blood pressure based on age and height which is not controlled by one anti-hypertensive medication
    • Patients aged > 17 years: systolic blood pressure >= 140 mmHg and/or diastolic blood pressure >= 90 mmHg that is not controlled by one anti-hypertensive medication
  • Prior Therapy:

    • Patients must have had no prior anthracycline (e.g., doxorubicin, daunorubicin) or ifosfamide chemotherapy
    • Patients must have had no prior use of pazopanib or similar multi-targeted tyrosine kinase inhibitors (TKI)
    • Patients must have had no prior radiotherapy to tumor-involved sites
    • Note: patients previously treated for a non-NRSTS cancer are eligible provided they meet the prior therapy requirements; patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier are excluded
  • Other types of invasive malignancy that are not disease free within 3 years except for non-melanoma skin cancer, lentigo maligna, any carcinoma-in-situ or prostate cancer with low risk factors
  • CYTOCHROME P450 3A4 (CYP3A4) substrates WITH narrow therapeutic indices: patients chronically receiving medications known to be metabolized by CYP3A4 and with narrow therapeutic indices within 7 days prior to study enrollment, including but not limited to pimozide, aripiprazole, triazolam, ergotamine and halofantrine are not eligible; Note: the use of fentanyl is permitted
  • CYP3A4 Inhibitors: patients chronically receiving drugs that are known potent CYP3A4 inhibitors within 7 days prior to study enrollment, including but not limited to itraconazole, clarithromycin, erythromycin many non-nucleoside reverse-transcriptase inhibitors (NNRTIs), diltiazem, verapamil, and grapefruit juice are not eligible
  • CYP3A4 Inducers: patients chronically receiving drugs that are known potent CYP3A4 inducers within 14 days prior to study enrollment, including but not limited to carbamazepine, phenobarbital, phenytoin, rifampin, and St. John's wort are not eligible (with the exception of glucocorticoids)
  • Certain medications that are associated with a risk for QTc prolongation and/or Torsades de Pointes, although not prohibited, should be avoided or replaced with medications that do not carry these risks, if possible
  • Subjects with any condition that may impair the ability to swallow or absorb oral medications/investigational product including:

    • Any lesion, whether induced by tumor, radiation or other conditions, which makes it difficult to swallow capsules or pills
    • Prior surgical procedures affecting absorption including, but not limited to major resection of stomach or small bowel
    • Active peptic ulcer disease
    • Malabsorption syndrome
  • Subjects with any condition that may increase the risk of gastrointestinal bleeding or gastrointestinal perforation, including:

    • Active peptic ulcer disease
    • Known intraluminal metastatic lesions
    • Inflammatory bowel disease (e.g., ulcerative colitis, Crohn's disease) or other gastrointestinal conditions which increase the risk of perforation
    • History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 28 days prior to beginning study treatment
  • Subjects with any of the following cardiovascular conditions within the past 6 months

    • Cerebrovascular accident (CVA) or transient ischemic attack (TIA)
    • Cardiac arrhythmia
    • Admission for unstable angina
    • Cardiac angioplasty or stenting
    • Coronary artery bypass graft surgery
    • Pulmonary embolism, untreated deep venous thrombosis (DVT) or DVT which has been treated with therapeutic anticoagulation for less than 6 weeks
    • Arterial thrombosis
    • Symptomatic peripheral vascular disease
    • Class III or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system; a subject who has a history of class II heart failure and is asymptomatic on treatment may be considered eligible
  • History of serious or non-healing wound, ulcer, or bone fracture
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Patients who are unable to swallow whole tablets are not eligible
  • Patients with a body surface area < 0.5 m^2 are not eligible
  • Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible
  • Patients who are receiving any other investigational agent(s)
  • Pregnancy and breast feeding:

    • Female patients who are pregnant are ineligible
    • Lactating females are not eligible unless they have agreed not to breastfeed their infants during treatment and for a period of 1 month following completion of treatment
    • Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained
  • Unwillingness to use an effective contraceptive method for the duration of their study participation and for at least 1 month after treatment is completed if sexually active with reproductive potential
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02180867


  Hide Study Locations
Locations
United States, Alabama
Children's Hospital of Alabama Recruiting
Birmingham, Alabama, United States, 35233
Contact: Alyssa T. Reddy       helpdesk@childrensoncologygroup.org   
Principal Investigator: Alyssa T. Reddy         
The Kirklin Clinic at Acton Road Recruiting
Birmingham, Alabama, United States, 35243
Contact: Alyssa T. Reddy    888-823-5923    ctsucontact@westat.com   
Principal Investigator: Alyssa T. Reddy         
United States, Alaska
Anchorage Associates in Radiation Medicine Suspended
Anchorage, Alaska, United States, 98508
Alaska Breast Care and Surgery LLC Suspended
Anchorage, Alaska, United States, 99508
Alaska Oncology and Hematology LLC Suspended
Anchorage, Alaska, United States, 99508
Alaska Women's Cancer Care Recruiting
Anchorage, Alaska, United States, 99508
Contact: Eugenia Chang    888-823-5923    ctsucontact@westat.com   
Principal Investigator: Eugenia Chang         
Anchorage Oncology Centre Suspended
Anchorage, Alaska, United States, 99508
Katmai Oncology Group Suspended
Anchorage, Alaska, United States, 99508
Providence Alaska Medical Center Suspended
Anchorage, Alaska, United States, 99508
United States, Arizona
Cardon Children's Medical Center Recruiting
Mesa, Arizona, United States, 85202
Contact: Erlyn C. Smith       helpdesk@childrensoncologygroup.org   
Principal Investigator: Erlyn C. Smith         
Phoenix Childrens Hospital Recruiting
Phoenix, Arizona, United States, 85016
Contact: Jessica Boklan    602-546-0920      
Principal Investigator: Jessica Boklan         
The University of Arizona Medical Center-University Campus Recruiting
Tucson, Arizona, United States, 85724
Contact: Lisa M. Kopp    520-626-9008      
Principal Investigator: Lisa M. Kopp         
United States, Arkansas
Arkansas Children's Hospital Recruiting
Little Rock, Arkansas, United States, 72202-3591
Contact: David L. Becton    501-686-8274      
Principal Investigator: David L. Becton         
United States, California
Kaiser Permanente-Anaheim Recruiting
Anaheim, California, United States, 92807
Contact: Lara N. Durna    626-564-3455      
Principal Investigator: Lara N. Durna         
AIS Cancer Center at San Joaquin Community Hospital Suspended
Bakersfield, California, United States, 93301
Providence Saint Joseph Medical Center/Disney Family Cancer Center Suspended
Burbank, California, United States, 91505
Southern California Permanente Medical Group Recruiting
Downey, California, United States, 90242
Contact: Robert M. Cooper    626-564-3455      
Principal Investigator: Robert M. Cooper         
City of Hope Comprehensive Cancer Center Recruiting
Duarte, California, United States, 91010
Contact: Anna B. Pawlowska    800-826-4673    becomingapatient@coh.org   
Principal Investigator: Anna B. Pawlowska         
Loma Linda University Medical Center Recruiting
Loma Linda, California, United States, 92354
Contact: Albert Kheradpour    909-558-3375      
Principal Investigator: Albert Kheradpour         
Miller Children's and Women's Hospital Long Beach Recruiting
Long Beach, California, United States, 90806
Contact: Pamela H. Kempert       helpdesk@childrensoncologygroup.org   
Principal Investigator: Pamela H. Kempert         
Children's Hospital Los Angeles Recruiting
Los Angeles, California, United States, 90027
Contact: Leo Mascarenhas       helpdesk@childrensoncologygroup.org   
Principal Investigator: Leo Mascarenhas         
Kaiser Permanente Los Angeles Medical Center Recruiting
Los Angeles, California, United States, 90027
Contact: Lara N. Durna    626-564-3455      
Principal Investigator: Lara N. Durna         
Los Angeles County-USC Medical Center Recruiting
Los Angeles, California, United States, 90033
Contact: James S. Hu    323-865-0451      
Principal Investigator: James S. Hu         
USC / Norris Comprehensive Cancer Center Recruiting
Los Angeles, California, United States, 90033
Contact: James S. Hu    323-865-0451      
Principal Investigator: James S. Hu         
Children's Hospital Central California Recruiting
Madera, California, United States, 93636-8762
Contact: Vonda L. Crouse       helpdesk@childrensoncologygroup.org   
Principal Investigator: Vonda L. Crouse         
Children's Hospital and Research Center at Oakland Recruiting
Oakland, California, United States, 94609-1809
Contact: Carla B. Golden       helpdesk@childrensoncologygroup.org   
Principal Investigator: Carla B. Golden         
Kaiser Permanente-Oakland Recruiting
Oakland, California, United States, 94611
Contact: Samantha A. Seaward    877-827-3222      
Principal Investigator: Samantha A. Seaward         
Children's Hospital of Orange County Recruiting
Orange, California, United States, 92868
Contact: Elyssa M. Rubin       helpdesk@childrensoncologygroup.org   
Principal Investigator: Elyssa M. Rubin         
Lucile Packard Children's Hospital Stanford University Recruiting
Palo Alto, California, United States, 94304
Contact: Sheri L. Spunt    650-498-7061    ccto-office@stanford.edu   
Principal Investigator: Sheri L. Spunt         
Stanford Cancer Institute Palo Alto Recruiting
Palo Alto, California, United States, 94304
Contact: Lynn Million    650-498-7061    ccto-office@stanford.edu   
Principal Investigator: Lynn Million         
Kaiser Permanente-Riverside Recruiting
Riverside, California, United States, 92505
Contact: Lara N. Durna    626-564-3455      
Principal Investigator: Lara N. Durna         
Sutter Medical Center Sacramento Recruiting
Sacramento, California, United States, 95816
Contact: Yung S. Yim    415-209-2686    bernicl@sutterhealth.org   
Principal Investigator: Yung S. Yim         
University of California Davis Comprehensive Cancer Center Recruiting
Sacramento, California, United States, 95817
Contact: Marcio H. Malogolowkin    916-734-3089      
Principal Investigator: Marcio H. Malogolowkin         
Kaiser Permanente-San Diego Zion Recruiting
San Diego, California, United States, 92120
Contact: Lara N. Durna    626-564-3455      
Principal Investigator: Lara N. Durna         
Rady Children's Hospital - San Diego Recruiting
San Diego, California, United States, 92123
Contact: William D. Roberts       helpdesk@childrensoncologygroup.org   
Principal Investigator: William D. Roberts         
UCSF Medical Center-Mission Bay Recruiting
San Francisco, California, United States, 94158
Contact: Robert E. Goldsby    877-827-3222      
Principal Investigator: Robert E. Goldsby         
Kaiser Permanente-San Marcos Recruiting
San Marcos, California, United States, 92069
Contact: Lara N. Durna    626-564-3455      
Principal Investigator: Lara N. Durna         
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Recruiting
Torrance, California, United States, 90502
Contact: Eduard H. Panosyan    310-222-3621      
Principal Investigator: Eduard H. Panosyan         
Gene Upshaw Memorial Tahoe Forest Cancer Center Suspended
Truckee, California, United States, 96161
United States, Colorado
Children's Hospital Colorado Recruiting
Aurora, Colorado, United States, 80045
Contact: Timothy P. Garrington       helpdesk@childrensoncologygroup.org   
Principal Investigator: Timothy P. Garrington         
University of Colorado Hospital Recruiting
Aurora, Colorado, United States, 80045
Contact: Timothy P. Garrington    888-823-5923    ctsucontact@westat.com   
Principal Investigator: Timothy P. Garrington         
Memorial Hospital Central Suspended
Colorado Springs, Colorado, United States, 80909
Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center Recruiting
Denver, Colorado, United States, 80218
Contact: Jennifer J. Clark       helpdesk@childrensoncologygroup.org   
Principal Investigator: Jennifer J. Clark         
Poudre Valley Hospital Suspended
Fort Collins, Colorado, United States, 80524
United States, Connecticut
Connecticut Children's Medical Center Recruiting
Hartford, Connecticut, United States, 06106
Contact: Michael S. Isakoff    800-579-7822      
Principal Investigator: Michael S. Isakoff         
Yale University Recruiting
New Haven, Connecticut, United States, 06520
Contact: Nina S. Kadan-Lottick    203-785-5702      
Principal Investigator: Nina S. Kadan-Lottick         
United States, Delaware
Alfred I duPont Hospital for Children Recruiting
Wilmington, Delaware, United States, 19803
Contact: Scott M. Bradfield       helpdesk@childrensoncologygroup.org   
Principal Investigator: Scott M. Bradfield         
United States, District of Columbia
MedStar Georgetown University Hospital Recruiting
Washington, District of Columbia, United States, 20007
Contact: Corina E. Gonzalez    202-444-2223      
Principal Investigator: Corina E. Gonzalez         
Children's National Medical Center Recruiting
Washington, District of Columbia, United States, 20010
Contact: Jeffrey S. Dome       helpdesk@childrensoncologygroup.org   
Principal Investigator: Jeffrey S. Dome         
United States, Florida
UM Sylvester Comprehensive Cancer Center at Deerfield Beach Recruiting
Deerfield Beach, Florida, United States, 33442
Contact: Julio C. Barredo    305-243-2647      
Principal Investigator: Julio C. Barredo         
Golisano Children's Hospital of Southwest Florida Recruiting
Fort Myers, Florida, United States, 33908
Contact: Emad K. Salman    877-680-0008      
Principal Investigator: Emad K. Salman         
University of Florida Health Science Center - Gainesville Recruiting
Gainesville, Florida, United States, 32610
Contact: William B. Slayton       helpdesk@childrensoncologygroup.org   
Principal Investigator: William B. Slayton         
Memorial Regional Hospital/Joe DiMaggio Children's Hospital Recruiting
Hollywood, Florida, United States, 33021
Contact: Iftikhar Hanif       helpdesk@childrensoncologygroup.org   
Principal Investigator: Iftikhar Hanif         
Nemours Children's Clinic-Jacksonville Recruiting
Jacksonville, Florida, United States, 32207
Contact: Scott M. Bradfield       helpdesk@childrensoncologygroup.org   
Principal Investigator: Scott M. Bradfield         
University of Miami Miller School of Medicine-Sylvester Cancer Center Recruiting
Miami, Florida, United States, 33136
Contact: Julio C. Barredo    305-243-2647      
Principal Investigator: Julio C. Barredo         
Nicklaus Children's Hospital Recruiting
Miami, Florida, United States, 33155
Contact: Enrique A. Escalon       helpdesk@childrensoncologygroup.org   
Principal Investigator: Enrique A. Escalon         
Florida Hospital Orlando Recruiting
Orlando, Florida, United States, 32803
Contact: Fouad M. Hajjar    407-303-2090    FH.Cancer.Research@flhosp.org   
Principal Investigator: Fouad M. Hajjar         
Nemours Children's Hospital Recruiting
Orlando, Florida, United States, 32827
Contact: Scott M. Bradfield       helpdesk@childrensoncologygroup.org   
Principal Investigator: Scott M. Bradfield         
Nemours Children's Clinic - Pensacola Recruiting
Pensacola, Florida, United States, 32504
Contact: Scott M. Bradfield       helpdesk@childrensoncologygroup.org   
Principal Investigator: Scott M. Bradfield         
Johns Hopkins All Children's Hospital Recruiting
Saint Petersburg, Florida, United States, 33701
Contact: Jonathan L. Metts       helpdesk@childrensoncologygroup.org   
Principal Investigator: Jonathan L. Metts         
Saint Joseph's Hospital/Children's Hospital-Tampa Recruiting
Tampa, Florida, United States, 33607
Contact: Mark J. Mogul       helpdesk@childrensoncologygroup.org   
Principal Investigator: Mark J. Mogul         
Moffitt Cancer Center Recruiting
Tampa, Florida, United States, 33612
Contact: Damon R. Reed    800-456-7121    canceranswers@moffitt.org   
Principal Investigator: Damon R. Reed         
Saint Mary's Hospital Recruiting
West Palm Beach, Florida, United States, 33407
Contact: Narayana Gowda       helpdesk@childrensoncologygroup.org   
Principal Investigator: Narayana Gowda         
United States, Georgia
Emory University Hospital Midtown Recruiting
Atlanta, Georgia, United States, 30308
Contact: William Read    858-822-5354    cancercto@ucsd.edu   
Principal Investigator: William Read         
Children's Healthcare of Atlanta - Egleston Recruiting
Atlanta, Georgia, United States, 30322
Contact: Thomas A. Olson       helpdesk@childrensoncologygroup.org   
Principal Investigator: Thomas A. Olson         
Emory University Hospital/Winship Cancer Institute Recruiting
Atlanta, Georgia, United States, 30322
Contact: William Read    858-822-5354    cancercto@ucsd.edu   
Principal Investigator: William Read         
Augusta University Medical Center Recruiting
Augusta, Georgia, United States, 30912
Contact: Colleen H. McDonough    706-721-1663    cancer@augusta.edu   
Principal Investigator: Colleen H. McDonough         
Memorial University Medical Center Recruiting
Savannah, Georgia, United States, 31404
Contact: J. M. Johnston    912-350-8568      
Principal Investigator: J. M. Johnston         
United States, Hawaii
Straub Clinic and Hospital Recruiting
Honolulu, Hawaii, United States, 96813
Contact: Wade T. Kyono    808-586-2979      
Principal Investigator: Wade T. Kyono         
Kaiser Permanente Moanalua Medical Center Recruiting
Honolulu, Hawaii, United States, 96819
Contact: Wade T. Kyono    808-586-2979      
Principal Investigator: Wade T. Kyono         
Kapiolani Medical Center for Women and Children Recruiting
Honolulu, Hawaii, United States, 96826
Contact: Wade T. Kyono    808-586-2979      
Principal Investigator: Wade T. Kyono         
United States, Idaho
Saint Luke's Mountain States Tumor Institute Recruiting
Boise, Idaho, United States, 83712
Contact: Eugenia Chang       helpdesk@childrensoncologygroup.org   
Principal Investigator: Eugenia Chang         
Saint Luke's Mountain States Tumor Institute - Fruitland Suspended
Fruitland, Idaho, United States, 83619
Saint Luke's Mountain States Tumor Institute - Meridian Suspended
Meridian, Idaho, United States, 83642
Saint Luke's Mountain States Tumor Institute - Nampa Suspended
Nampa, Idaho, United States, 83686
Saint Luke's Mountain States Tumor Institute-Twin Falls Suspended
Twin Falls, Idaho, United States, 83301
United States, Illinois
Lurie Children's Hospital-Chicago Recruiting
Chicago, Illinois, United States, 60611
Contact: David O. Walterhouse       helpdesk@childrensoncologygroup.org   
Principal Investigator: David O. Walterhouse         
Northwestern University Recruiting
Chicago, Illinois, United States, 60611
Contact: Mark Agulnik    312-695-1301    cancer@northwestern.edu   
Principal Investigator: Mark Agulnik         
Rush University Medical Center Recruiting
Chicago, Illinois, United States, 60612
Contact: Dian Wang    312-942-5498    clinical_trials@rush.edu   
Principal Investigator: Dian Wang         
University of Illinois Recruiting
Chicago, Illinois, United States, 60612
Contact: Mary L. Schmidt    312-355-3046      
Principal Investigator: Mary L. Schmidt         
University of Chicago Comprehensive Cancer Center Recruiting
Chicago, Illinois, United States, 60637
Contact: Susan L. Cohn    773-834-7424      
Principal Investigator: Susan L. Cohn         
Northwestern Medicine Cancer Center Delnor Recruiting
Geneva, Illinois, United States, 60134
Contact: Robert M. Eisner    630-315-1918    Claudine.Gamster@CadenceHealth.org   
Principal Investigator: Robert M. Eisner         
Loyola University Medical Center Recruiting
Maywood, Illinois, United States, 60153
Contact: Eugene Suh    708-226-4357      
Principal Investigator: Eugene Suh         
Good Samaritan Regional Health Center Recruiting
Mount Vernon, Illinois, United States, 62864
Contact: Jay W. Carlson    888-221-4849      
Principal Investigator: Jay W. Carlson         
UC Comprehensive Cancer Center at Silver Cross Recruiting
New Lenox, Illinois, United States, 60451
Contact: Susan L. Cohn    773-834-7424      
Principal Investigator: Susan L. Cohn         
Advocate Children's Hospital-Oak Lawn Recruiting
Oak Lawn, Illinois, United States, 60453
Contact: Rebecca E. McFall       helpdesk@childrensoncologygroup.org   
Principal Investigator: Rebecca E. McFall         
Advocate Children's Hospital-Park Ridge Recruiting
Park Ridge, Illinois, United States, 60068
Contact: Caroline Y. Hu    847-384-3621      
Principal Investigator: Caroline Y. Hu         
Saint Jude Midwest Affiliate Recruiting
Peoria, Illinois, United States, 61637
Contact: Pedro A. De Alarcon    888-226-4343      
Principal Investigator: Pedro A. De Alarcon         
Saint John's Hospital Recruiting
Springfield, Illinois, United States, 62702
Contact: Gregory P. Brandt    217-545-7929      
Principal Investigator: Gregory P. Brandt         
Southern Illinois University School of Medicine Recruiting
Springfield, Illinois, United States, 62702
Contact: Gregory P. Brandt    217-545-7929      
Principal Investigator: Gregory P. Brandt         
Memorial Medical Center Recruiting
Springfield, Illinois, United States, 62781
Contact: Gregory P. Brandt    217-545-7929      
Principal Investigator: Gregory P. Brandt         
Northwestern Medicine Cancer Center Warrenville Recruiting
Warrenville, Illinois, United States, 60555
Contact: Robert M. Eisner    630-315-1918    Claudine.Gamster@CadenceHealth.org   
Principal Investigator: Robert M. Eisner         
United States, Indiana
Riley Hospital for Children Recruiting
Indianapolis, Indiana, United States, 46202
Contact: Kamnesh R. Pradhan    800-248-1199      
Principal Investigator: Kamnesh R. Pradhan         
Saint Vincent Hospital and Health Care Center Recruiting
Indianapolis, Indiana, United States, 46260
Contact: Bassem I. Razzouk    317-338-2194    research@stvincent.org   
Principal Investigator: Bassem I. Razzouk         
Reid Health Suspended
Richmond, Indiana, United States, 47374
United States, Iowa
Blank Children's Hospital Recruiting
Des Moines, Iowa, United States, 50309
Contact: Wendy L. Woods-Swafford    515-241-3305    rbehrens@cancercenterofiowa.com   
Principal Investigator: Wendy L. Woods-Swafford         
Iowa Methodist Medical Center Recruiting
Des Moines, Iowa, United States, 50309
Contact: Robert J. Behrens    515-239-2621      
Principal Investigator: Robert J. Behrens         
Medical Oncology and Hematology Associates-Des Moines Recruiting
Des Moines, Iowa, United States, 50309
Contact: Robert J. Behrens    515-239-2621      
Principal Investigator: Robert J. Behrens         
Broadlawns Medical Center Recruiting
Des Moines, Iowa, United States, 50314
Contact: Robert J. Behrens    515-239-2621      
Principal Investigator: Robert J. Behrens         
Iowa Lutheran Hospital Recruiting
Des Moines, Iowa, United States, 50316
Contact: Robert J. Behrens    515-239-2621      
Principal Investigator: Robert J. Behrens         
University of Iowa/Holden Comprehensive Cancer Center Recruiting
Iowa City, Iowa, United States, 52242
Contact: Mariko Sato    800-237-1225      
Principal Investigator: Mariko Sato         
Siouxland Regional Cancer Center Suspended
Sioux City, Iowa, United States, 51101
Methodist West Hospital Recruiting
West Des Moines, Iowa, United States, 50266-7700
Contact: Robert J. Behrens    515-239-2621      
Principal Investigator: Robert J. Behrens         
United States, Kansas
Newman Regional Health Recruiting
Emporia, Kansas, United States, 66801
Contact: Joshua M. Mammen    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Joshua M. Mammen         
Saint Catherine Hospital Recruiting
Garden City, Kansas, United States, 67846
Contact: Joshua M. Mammen    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Joshua M. Mammen         
Heartland Cancer Center Recruiting
Great Bend, Kansas, United States, 67530
Contact: Joshua M. Mammen    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Joshua M. Mammen         
Saint Rose Ambulatory and Surgery Center Suspended
Great Bend, Kansas, United States, 67530
Hays Medical Center Recruiting
Hays, Kansas, United States, 67601
Contact: Joshua M. Mammen    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Joshua M. Mammen         
University of Kansas Cancer Center Recruiting
Kansas City, Kansas, United States, 66160
Contact: Joshua M. Mammen    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Joshua M. Mammen         
Olathe Medical Center Recruiting
Olathe, Kansas, United States, 66061
Contact: Joshua M. Mammen    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Joshua M. Mammen         
University of Kansas Cancer Center-Overland Park Recruiting
Overland Park, Kansas, United States, 66210
Contact: Joshua M. Mammen    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Joshua M. Mammen         
Via Christi Hospital-Pittsburg Recruiting
Pittsburg, Kansas, United States, 66762
Contact: Joshua M. Mammen    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Joshua M. Mammen         
Salina Regional Health Center Recruiting
Salina, Kansas, United States, 67401
Contact: Joshua M. Mammen    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Joshua M. Mammen         
Saint Francis Hospital and Medical Center - Topeka Recruiting
Topeka, Kansas, United States, 66606
Contact: Joshua M. Mammen    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Joshua M. Mammen         
United States, Kentucky
University of Kentucky/Markey Cancer Center Recruiting
Lexington, Kentucky, United States, 40536
Contact: Lars M. Wagner    859-257-3379      
Principal Investigator: Lars M. Wagner         
Norton Children's Hospital Suspended
Louisville, Kentucky, United States, 40202
Norton Hospital Pavilion and Medical Campus Active, not recruiting
Louisville, Kentucky, United States, 40202
Norton Suburban Hospital and Medical Campus Active, not recruiting
Louisville, Kentucky, United States, 40207
United States, Louisiana
Children's Hospital New Orleans Recruiting
New Orleans, Louisiana, United States, 70118
Contact: Lolie C. Yu       helpdesk@childrensoncologygroup.org   
Principal Investigator: Lolie C. Yu         
Ochsner Medical Center Jefferson Recruiting
New Orleans, Louisiana, United States, 70121
Contact: Craig Lotterman    504-842-3708      
Principal Investigator: Craig Lotterman         
United States, Maine
Eastern Maine Medical Center Recruiting
Bangor, Maine, United States, 04401
Contact: Nadine P. SantaCruz    207-973-4274      
Principal Investigator: Nadine P. SantaCruz         
Maine Children's Cancer Program Recruiting
Scarborough, Maine, United States, 04074
Contact: Aaron R. Weiss       helpdesk@childrensoncologygroup.org   
Principal Investigator: Aaron R. Weiss         
United States, Maryland
Sinai Hospital of Baltimore Recruiting
Baltimore, Maryland, United States, 21215
Contact: Jason M. Fixler    410-601-6120    pridgely@lifebridgehealth.org   
Principal Investigator: Jason M. Fixler         
Johns Hopkins University/Sidney Kimmel Cancer Center Recruiting
Baltimore, Maryland, United States, 21287
Contact: Christine A. Pratilas    410-955-8804    jhcccro@jhmi.edu   
Principal Investigator: Christine A. Pratilas         
Walter Reed National Military Medical Center Recruiting
Bethesda, Maryland, United States, 20889-5600
Contact: Kenneth H. Lieuw    301-319-2100      
Principal Investigator: Kenneth H. Lieuw         
United States, Massachusetts
Massachusetts General Hospital Cancer Center Recruiting
Boston, Massachusetts, United States, 02114
Contact: Alison M. Friedmann    877-726-5130      
Principal Investigator: Alison M. Friedmann         
Dana-Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02215
Contact: Alison M. Friedmann    877-726-5130      
Principal Investigator: Alison M. Friedmann         
University of Massachusetts Medical School Recruiting
Worcester, Massachusetts, United States, 01655
Contact: Christopher P. Keuker    508-856-6265      
Principal Investigator: Christopher P. Keuker         
United States, Michigan
C S Mott Children's Hospital Recruiting
Ann Arbor, Michigan, United States, 48109
Contact: Rajen Mody       helpdesk@childrensoncologygroup.org   
Principal Investigator: Rajen Mody         
Bronson Battle Creek Recruiting
Battle Creek, Michigan, United States, 49017
Contact: Kathleen J. Yost    616-391-1230    crcwm-regulatory@crcwm.org   
Principal Investigator: Kathleen J. Yost         
Henry Ford Cancer Institute¿Downriver Recruiting
Brownstown, Michigan, United States, 48183
Contact: Robert A. Chapman    313-916-1784      
Principal Investigator: Robert A. Chapman         
Henry Ford Macomb Hospital-Clinton Township Recruiting
Clinton Township, Michigan, United States, 48038
Contact: Robert A. Chapman    313-916-1784      
Principal Investigator: Robert A. Chapman         
Wayne State University/Karmanos Cancer Institute Recruiting
Detroit, Michigan, United States, 48201
Contact: Zhihong J. Wang    313-576-9363      
Principal Investigator: Zhihong J. Wang         
Henry Ford Hospital Recruiting
Detroit, Michigan, United States, 48202
Contact: Robert A. Chapman    313-916-1784      
Principal Investigator: Robert A. Chapman         
Saint John Hospital and Medical Center Recruiting
Detroit, Michigan, United States, 48236
Contact: Adonis N. Lorenzana    313-343-3166      
Principal Investigator: Adonis N. Lorenzana         
Michigan State University Clinical Center Suspended
East Lansing, Michigan, United States, 48824-7016
Hurley Medical Center Recruiting
Flint, Michigan, United States, 48502
Contact: Nkechi Onwuzurike    810-762-8057      
Principal Investigator: Nkechi Onwuzurike         
Helen DeVos Children's Hospital at Spectrum Health Recruiting
Grand Rapids, Michigan, United States, 49503
Contact: Kathleen J. Yost    616-391-1230    crcwm-regulatory@crcwm.org   
Principal Investigator: Kathleen J. Yost         
Mercy Health Saint Mary's Recruiting
Grand Rapids, Michigan, United States, 49503
Contact: Kathleen J. Yost    616-391-1230    crcwm-regulatory@crcwm.org   
Principal Investigator: Kathleen J. Yost         
Spectrum Health at Butterworth Campus Recruiting
Grand Rapids, Michigan, United States, 49503
Contact: Kathleen J. Yost    616-391-1230    crcwm-regulatory@crcwm.org   
Principal Investigator: Kathleen J. Yost         
Borgess Medical Center Recruiting
Kalamazoo, Michigan, United States, 49001
Contact: Kathleen J. Yost    616-391-1230    crcwm-regulatory@crcwm.org   
Principal Investigator: Kathleen J. Yost         
Bronson Methodist Hospital Recruiting
Kalamazoo, Michigan, United States, 49007
Contact: Kathleen J. Yost    616-391-1230    crcwm-regulatory@crcwm.org   
Principal Investigator: Kathleen J. Yost         
West Michigan Cancer Center Recruiting
Kalamazoo, Michigan, United States, 49007
Contact: Kathleen J. Yost    616-391-1230    crcwm-regulatory@crcwm.org   
Principal Investigator: Kathleen J. Yost         
Mercy Health Mercy Campus Recruiting
Muskegon, Michigan, United States, 49444
Contact: Kathleen J. Yost    616-391-1230    crcwm-regulatory@crcwm.org   
Principal Investigator: Kathleen J. Yost         
Lakeland Community Hospital Recruiting
Niles, Michigan, United States, 49120
Contact: Kathleen J. Yost    616-391-1230    crcwm-regulatory@crcwm.org   
Principal Investigator: Kathleen J. Yost         
Spectrum Health Reed City Hospital Recruiting
Reed City, Michigan, United States, 49677
Contact: Kathleen J. Yost    616-391-1230    crcwm-regulatory@crcwm.org   
Principal Investigator: Kathleen J. Yost         
Beaumont Children's Hospital-Royal Oak Recruiting
Royal Oak, Michigan, United States, 48073
Contact: Laura K. Gowans    248-551-7695      
Principal Investigator: Laura K. Gowans         
Lakeland Hospital Recruiting
Saint Joseph, Michigan, United States, 49085
Contact: Kathleen J. Yost    616-391-1230    crcwm-regulatory@crcwm.org   
Principal Investigator: Kathleen J. Yost         
Marie Yeager Cancer Center Recruiting
Saint Joseph, Michigan, United States, 49085
Contact: Kathleen J. Yost    616-391-1230    crcwm-regulatory@crcwm.org   
Principal Investigator: Kathleen J. Yost         
Munson Medical Center Recruiting
Traverse City, Michigan, United States, 49684
Contact: Kathleen J. Yost    616-391-1230    crcwm-regulatory@crcwm.org   
Principal Investigator: Kathleen J. Yost         
Henry Ford West Bloomfield Hospital Recruiting
West Bloomfield, Michigan, United States, 48322
Contact: Robert A. Chapman    313-916-1784      
Principal Investigator: Robert A. Chapman         
United States, Minnesota
Essentia Health Cancer Center Recruiting
Duluth, Minnesota, United States, 55805
Contact: Emily G. Greengard    888-823-5923    ctsucontact@westat.com   
Principal Investigator: Emily G. Greengard         
Children's Hospitals and Clinics of Minnesota - Minneapolis Recruiting
Minneapolis, Minnesota, United States, 55404
Contact: Michael K. Richards       helpdesk@childrensoncologygroup.org   
Principal Investigator: Michael K. Richards         
University of Minnesota/Masonic Cancer Center Recruiting
Minneapolis, Minnesota, United States, 55455
Contact: Emily G. Greengard       helpdesk@childrensoncologygroup.org   
Principal Investigator: Emily G. Greengard         
Mayo Clinic Recruiting
Rochester, Minnesota, United States, 55905
Contact: Carola A. Arndt    855-776-0015      
Principal Investigator: Carola A. Arndt         
United States, Mississippi
University of Mississippi Medical Center Suspended
Jackson, Mississippi, United States, 39216
United States, Missouri
Columbia Regional Suspended
Columbia, Missouri, United States, 65201
Siteman Cancer Center at West County Hospital Recruiting
Creve Coeur, Missouri, United States, 63141
Contact: Frederick S. Huang    800-600-3606    info@siteman.wustl.edu   
Principal Investigator: Frederick S. Huang         
Freeman Health System Recruiting
Joplin, Missouri, United States, 64804
Contact: Jay W. Carlson    888-221-4849      
Principal Investigator: Jay W. Carlson         
The Childrens Mercy Hospital Suspended
Kansas City, Missouri, United States, 64108
The University of Kansas Cancer Center-South Recruiting
Kansas City, Missouri, United States, 64131
Contact: Joshua M. Mammen    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Joshua M. Mammen         
The University of Kansas Cancer Center-North Recruiting
Kansas City, Missouri, United States, 64154
Contact: Joshua M. Mammen    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Joshua M. Mammen         
The University of Kansas Cancer Center-Lee's Summit Recruiting
Lee's Summit, Missouri, United States, 64064
Contact: Joshua M. Mammen    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Joshua M. Mammen         
Delbert Day Cancer Institute at PCRMC Recruiting
Rolla, Missouri, United States, 65401
Contact: Jay W. Carlson    888-221-4849      
Principal Investigator: Jay W. Carlson         
Saint John's Clinic-Rolla-Cancer and Hematology Recruiting
Rolla, Missouri, United States, 65401
Contact: Jay W. Carlson    888-221-4849      
Principal Investigator: Jay W. Carlson         
Cardinal Glennon Children's Medical Center Recruiting
Saint Louis, Missouri, United States, 63104
Contact: William S. Ferguson       helpdesk@childrensoncologygroup.org   
Principal Investigator: William S. Ferguson         
Washington University School of Medicine Recruiting
Saint Louis, Missouri, United States, 63110
Contact: Frederick S. Huang    800-600-3606    info@siteman.wustl.edu   
Principal Investigator: Frederick S. Huang         
Mercy Hospital Saint Louis Recruiting
Saint Louis, Missouri, United States, 63141
Contact: Jay W. Carlson    888-221-4849      
Principal Investigator: Jay W. Carlson         
Mercy Hospital Springfield Recruiting
Springfield, Missouri, United States, 65804
Contact: Jay W. Carlson    888-221-4849      
Principal Investigator: Jay W. Carlson         
CoxHealth South Hospital Recruiting
Springfield, Missouri, United States, 65807
Contact: Jay W. Carlson    888-221-4849      
Principal Investigator: Jay W. Carlson         
United States, Nebraska
Children's Hospital and Medical Center of Omaha Recruiting
Omaha, Nebraska, United States, 68114
Contact: Minnie Abromowitch       helpdesk@childrensoncologygroup.org   
Principal Investigator: Minnie Abromowitch         
University of Nebraska Medical Center Recruiting
Omaha, Nebraska, United States, 68198
Contact: Minnie Abromowitch       helpdesk@childrensoncologygroup.org   
Principal Investigator: Minnie Abromowitch         
United States, Nevada
Nevada Cancer Research Foundation CCOP Recruiting
Las Vegas, Nevada, United States, 89106
Contact: Jonathan Bernstein    702-384-0013      
Principal Investigator: Jonathan Bernstein         
Radiation Oncology Centers of Nevada Central Recruiting
Las Vegas, Nevada, United States, 89106
Contact: Alan K. Ikeda    702-384-0013      
Principal Investigator: Alan K. Ikeda         
21st Century Oncology Recruiting
Las Vegas, Nevada, United States, 89109
Contact: Alan K. Ikeda    702-384-0013      
Principal Investigator: Alan K. Ikeda         
Children's Specialty Center of Nevada II Recruiting
Las Vegas, Nevada, United States, 89109
Contact: Alan K. Ikeda    702-384-0013      
Principal Investigator: Alan K. Ikeda         
Summerlin Hospital Medical Center Recruiting
Las Vegas, Nevada, United States, 89144
Contact: Alan K. Ikeda    702-384-0013      
Principal Investigator: Alan K. Ikeda         
Comprehensive Cancer Centers of Nevada Recruiting
Las Vegas, Nevada, United States, 89148
Contact: Alan K. Ikeda    702-384-0013      
Principal Investigator: Alan K. Ikeda         
Renown Regional Medical Center Recruiting
Reno, Nevada, United States, 89502
Contact: Alan K. Ikeda    702-384-0013      
Principal Investigator: Alan K. Ikeda         
Saint Mary's Regional Medical Center Recruiting
Reno, Nevada, United States, 89503
Contact: Alan K. Ikeda    888-823-5923    ctsucontact@westat.com   
Principal Investigator: Alan K. Ikeda         
United States, New Hampshire
Dartmouth Hitchcock Medical Center Recruiting
Lebanon, New Hampshire, United States, 03756
Contact: Sara Chaffee    800-639-6918    cancer.research.nurse@dartmouth.edu   
Principal Investigator: Sara Chaffee         
United States, New Jersey
Hackensack University Medical Center Recruiting
Hackensack, New Jersey, United States, 07601
Contact: Burton E. Appel    201-996-2879      
Principal Investigator: Burton E. Appel         
Morristown Medical Center Recruiting
Morristown, New Jersey, United States, 07960
Contact: Steven L. Halpern    201-996-2879      
Principal Investigator: Steven L. Halpern         
Saint Peter's University Hospital Recruiting
New Brunswick, New Jersey, United States, 08901
Contact: Nibal A. Zaghloul       helpdesk@childrensoncologygroup.org   
Principal Investigator: Nibal A. Zaghloul         
Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital Recruiting
New Brunswick, New Jersey, United States, 08903
Contact: Richard A. Drachtman    732-235-8675      
Principal Investigator: Richard A. Drachtman         
Newark Beth Israel Medical Center Recruiting
Newark, New Jersey, United States, 07112
Contact: Peri Kamalakar    973-926-7230      
Principal Investigator: Peri Kamalakar         
Saint Joseph's Regional Medical Center Recruiting
Paterson, New Jersey, United States, 07503
Contact: Mary A. Bonilla       helpdesk@childrensoncologygroup.org   
Principal Investigator: Mary A. Bonilla         
United States, New Mexico
University of New Mexico Cancer Center Recruiting
Albuquerque, New Mexico, United States, 87102
Contact: Koh B. Boayue    505-925-0366    LByatt@nmcca.org   
Principal Investigator: Koh B. Boayue         
United States, New York
Albany Medical Center Recruiting
Albany, New York, United States, 12208
Contact: Vikramjit S. Kanwar    518-262-3368      
Principal Investigator: Vikramjit S. Kanwar         
Montefiore Medical Center-Einstein Campus Recruiting
Bronx, New York, United States, 10461
Contact: Lisa Figueiredo    718-904-2730    aecc@aecom.yu.edu   
Principal Investigator: Lisa Figueiredo         
Montefiore Medical Center-Weiler Hospital Recruiting
Bronx, New York, United States, 10461
Contact: Lisa Figueiredo    718-904-2730    aecc@aecom.yu.edu   
Principal Investigator: Lisa Figueiredo         
Montefiore Medical Center - Moses Campus Recruiting
Bronx, New York, United States, 10467-2490
Contact: Lisa Figueiredo    718-904-2730    aecc@aecom.yu.edu   
Principal Investigator: Lisa Figueiredo         
Roswell Park Cancer Institute Recruiting
Buffalo, New York, United States, 14263
Contact: Kilian E. Salerno    877-275-7724      
Principal Investigator: Kilian E. Salerno         
Glens Falls Hospital Recruiting
Glens Falls, New York, United States, 12801
Contact: Alan C. Homans    802-656-8990      
Principal Investigator: Alan C. Homans         
NYU Winthrop Hospital Recruiting
Mineola, New York, United States, 11501
Contact: Mark E. Weinblatt    516-663-3115      
Principal Investigator: Mark E. Weinblatt         
The Steven and Alexandra Cohen Children's Medical Center of New York Recruiting
New Hyde Park, New York, United States, 11040
Contact: Carolyn F. Levy       helpdesk@childrensoncologygroup.org   
Principal Investigator: Carolyn F. Levy         
Laura and Isaac Perlmutter Cancer Center at NYU Langone Recruiting
New York, New York, United States, 10016
Contact: Sharon L. Gardner    212-263-4434    prmc.coordinator@nyumc.org   
Principal Investigator: Sharon L. Gardner         
Mount Sinai Hospital Recruiting
New York, New York, United States, 10029
Contact: Birte Wistinghausen    212-824-7309    CCTO@mssm.edu   
Principal Investigator: Birte Wistinghausen         
Columbia University/Herbert Irving Cancer Center Recruiting
New York, New York, United States, 10032
Contact: Alice Lee    212-305-8615      
Principal Investigator: Alice Lee         
Weill Medical College of Cornell University Recruiting
New York, New York, United States, 10065
Contact: Elizabeta C. Popa    212-746-1848      
Principal Investigator: Elizabeta C. Popa         
University of Rochester Recruiting
Rochester, New York, United States, 14642
Contact: Jeffrey R. Andolina    585-275-5830      
Principal Investigator: Jeffrey R. Andolina         
State University of New York Upstate Medical University Recruiting
Syracuse, New York, United States, 13210
Contact: Philip M. Monteleone    315-464-5476      
Principal Investigator: Philip M. Monteleone         
New York Medical College Recruiting
Valhalla, New York, United States, 10595
Contact: Jessica C. Hochberg    914-594-3794      
Principal Investigator: Jessica C. Hochberg         
United States, North Carolina
Mission Hospital-Memorial Campus Recruiting
Asheville, North Carolina, United States, 28801
Contact: Douglas J. Scothorn    828-213-4150      
Principal Investigator: Douglas J. Scothorn         
UNC Lineberger Comprehensive Cancer Center Recruiting
Chapel Hill, North Carolina, United States, 27599
Contact: Stuart H. Gold    877-668-0683    cancerclinicaltrials@med.unc.edu   
Principal Investigator: Stuart H. Gold         
Carolinas Medical Center/Levine Cancer Institute Recruiting
Charlotte, North Carolina, United States, 28203
Contact: Joel A. Kaplan    704-355-2884      
Principal Investigator: Joel A. Kaplan         
Novant Health Presbyterian Medical Center Recruiting
Charlotte, North Carolina, United States, 28204
Contact: Jessica A. Bell    704-384-5369      
Principal Investigator: Jessica A. Bell         
Duke University Medical Center Recruiting
Durham, North Carolina, United States, 27710
Contact: Susan G. Kreissman    888-275-3853      
Principal Investigator: Susan G. Kreissman         
East Carolina University Recruiting
Greenville, North Carolina, United States, 27858
Contact: Beng R. Fuh    252-744-2391      
Principal Investigator: Beng R. Fuh         
Matthews Radiation Oncology Center Recruiting
Matthews, North Carolina, United States, 28105
Contact: Jessica A. Bell    704-384-5369      
Principal Investigator: Jessica A. Bell         
Wake Forest University Health Sciences Recruiting
Winston-Salem, North Carolina, United States, 27157
Contact: Thomas B. Russell    336-713-6771      
Principal Investigator: Thomas B. Russell         
United States, North Dakota
Sanford Broadway Medical Center Recruiting
Fargo, North Dakota, United States, 58122
Contact: Samuel O. Anim    800-437-4010      
Principal Investigator: Samuel O. Anim         
United States, Ohio
Children's Hospital Medical Center of Akron Recruiting
Akron, Ohio, United States, 44308
Contact: Steven J. Kuerbitz       helpdesk@childrensoncologygroup.org   
Principal Investigator: Steven J. Kuerbitz         
UHHS-Chagrin Highlands Medical Center Recruiting
Beachwood, Ohio, United States, 44122
Contact: Yousif (Joe) H. Matloub    216-844-5437      
Principal Investigator: Yousif (Joe) H. Matloub         
Cincinnati Children's Hospital Medical Center Recruiting
Cincinnati, Ohio, United States, 45229
Contact: Joseph G. Pressey       helpdesk@childrensoncologygroup.org   
Principal Investigator: Joseph G. Pressey         
Oncology Hematology Care Inc-Blue Ash Suspended
Cincinnati, Ohio, United States, 45242
Case Western Reserve University Recruiting
Cleveland, Ohio, United States, 44106
Contact: Yousif (Joe) H. Matloub    216-844-5437      
Principal Investigator: Yousif (Joe) H. Matloub         
Rainbow Babies and Childrens Hospital Recruiting
Cleveland, Ohio, United States, 44106
Contact: Yousif (Joe) H. Matloub    216-844-5437      
Principal Investigator: Yousif (Joe) H. Matloub         
Cleveland Clinic Foundation Recruiting
Cleveland, Ohio, United States, 44195
Contact: Aron Flagg    866-223-8100      
Principal Investigator: Aron Flagg         
Nationwide Children's Hospital Recruiting
Columbus, Ohio, United States, 43205
Contact: Mark A. Ranalli       helpdesk@childrensoncologygroup.org   
Principal Investigator: Mark A. Ranalli         
Ohio State University Comprehensive Cancer Center Recruiting
Columbus, Ohio, United States, 43210
Contact: Meng X. Welliver    800-293-5066    Jamesline@osumc.edu   
Principal Investigator: Meng X. Welliver         
Dayton Children's Hospital Recruiting
Dayton, Ohio, United States, 45404
Contact: Ayman A. El-Sheikh       helpdesk@childrensoncologygroup.org   
Principal Investigator: Ayman A. El-Sheikh         
Good Samaritan Hospital - Dayton Suspended
Dayton, Ohio, United States, 45406
Miami Valley Hospital Suspended
Dayton, Ohio, United States, 45409
Dayton Physicians LLC-Samaritan North Suspended
Dayton, Ohio, United States, 45415
Samaritan North Health Center Suspended
Dayton, Ohio, United States, 45415
Blanchard Valley Hospital Suspended
Findlay, Ohio, United States, 45840
Atrium Medical Center-Middletown Regional Hospital Suspended
Franklin, Ohio, United States, 45005-1066
Wayne Hospital Suspended
Greenville, Ohio, United States, 45331
Kettering Medical Center Suspended
Kettering, Ohio, United States, 45429
Springfield Regional Medical Center Suspended
Springfield, Ohio, United States, 45505
The Toledo Hospital/Toledo Children's Hospital Recruiting
Toledo, Ohio, United States, 43606
Contact: Jamie L. Dargart    419-824-1842      
Principal Investigator: Jamie L. Dargart         
Upper Valley Medical Center Suspended
Troy, Ohio, United States, 45373
Wright-Patterson Medical Center Suspended
Wright-Patterson Air Force Base, Ohio, United States, 45433-5529
United States, Oklahoma
University of Oklahoma Health Sciences Center Recruiting
Oklahoma City, Oklahoma, United States, 73104
Contact: Terence S. Herman    405-271-8777    ou-clinical-trials@ouhsc.edu   
Principal Investigator: Terence S. Herman         
Mercy Hospital Oklahoma City Recruiting
Oklahoma City, Oklahoma, United States, 73120
Contact: Jay W. Carlson    888-221-4849      
Principal Investigator: Jay W. Carlson         
Oklahoma Cancer Specialists and Research Institute-Tulsa Recruiting
Tulsa, Oklahoma, United States, 74146
Contact: Terence S. Herman    405-271-8777    ou-clinical-trials@ouhsc.edu   
Principal Investigator: Terence S. Herman         
United States, Oregon
Saint Charles Health System Suspended
Bend, Oregon, United States, 97701
Clackamas Radiation Oncology Center Suspended
Clackamas, Oregon, United States, 97015
Bay Area Hospital Suspended
Coos Bay, Oregon, United States, 97420
Providence Portland Medical Center Suspended
Portland, Oregon, United States, 97213
Providence Saint Vincent Medical Center Suspended
Portland, Oregon, United States, 97225
Legacy Emanuel Children's Hospital Recruiting
Portland, Oregon, United States, 97227
Contact: Janice F. Olson    503-413-8199      
Principal Investigator: Janice F. Olson         
Oregon Health and Science University Recruiting
Portland, Oregon, United States, 97239
Contact: Lara E. Davis    503-494-1080    trials@ohsu.edu   
Principal Investigator: Lara E. Davis         
United States, Pennsylvania
Lehigh Valley Hospital - Muhlenberg Recruiting
Bethlehem, Pennsylvania, United States, 18017
Contact: Lydia A. Boateng    484-884-2201      
Principal Investigator: Lydia A. Boateng         
Geisinger Medical Center Recruiting
Danville, Pennsylvania, United States, 17822
Contact: Jagadeesh Ramdas    570-271-5251      
Principal Investigator: Jagadeesh Ramdas         
Penn State Children's Hospital Recruiting
Hershey, Pennsylvania, United States, 17033
Contact: Lisa M. McGregor       helpdesk@childrensoncologygroup.org   
Principal Investigator: Lisa M. McGregor         
Drexel University School of Medicine Recruiting
Philadelphia, Pennsylvania, United States, 19102
Contact: Gregory E. Halligan    888-823-5923    ctsucontact@westat.com   
Principal Investigator: Gregory E. Halligan         
Children's Hospital of Philadelphia Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Richard B. Womer       helpdesk@childrensoncologygroup.org   
Principal Investigator: Richard B. Womer         
Thomas Jefferson University Hospital Recruiting
Philadelphia, Pennsylvania, United States, 19107
Contact: Atrayee B. Mallick    215-955-6084      
Principal Investigator: Atrayee B. Mallick         
Fox Chase Cancer Center Recruiting
Philadelphia, Pennsylvania, United States, 19111
Contact: Krisha J. Howell    215-728-4790      
Principal Investigator: Krisha J. Howell         
Saint Christopher's Hospital for Children Recruiting
Philadelphia, Pennsylvania, United States, 19134
Contact: Gregory E. Halligan       helpdesk@childrensoncologygroup.org   
Principal Investigator: Gregory E. Halligan         
Allegheny General Hospital Recruiting
Pittsburgh, Pennsylvania, United States, 15212
Contact: Christie J. Hilton    724-226-7380      
Principal Investigator: Christie J. Hilton         
Children's Hospital of Pittsburgh of UPMC Recruiting
Pittsburgh, Pennsylvania, United States, 15224
Contact: Jean M. Tersak       helpdesk@childrensoncologygroup.org   
Principal Investigator: Jean M. Tersak         
Lankenau Medical Center Suspended
Wynnewood, Pennsylvania, United States, 19096
United States, Rhode Island
Rhode Island Hospital Recruiting
Providence, Rhode Island, United States, 02903
Contact: Jennifer J. Greene Welch    401-444-1488      
Principal Investigator: Jennifer J. Greene Welch         
United States, South Carolina
Medical University of South Carolina Recruiting
Charleston, South Carolina, United States, 29425
Contact: Jacqueline M. Kraveka    843-792-9321      
Principal Investigator: Jacqueline M. Kraveka         
Palmetto Health Richland Recruiting
Columbia, South Carolina, United States, 29203
Contact: Stuart L. Cramer    803-434-3680      
Principal Investigator: Stuart L. Cramer         
Saint Francis Hospital Recruiting
Greenville, South Carolina, United States, 29601
Contact: Robert D. Siegel    864-255-1713      
Principal Investigator: Robert D. Siegel         
BI-LO Charities Children's Cancer Center Recruiting
Greenville, South Carolina, United States, 29605
Contact: Nichole L. Bryant       helpdesk@childrensoncologygroup.org   
Principal Investigator: Nichole L. Bryant         
Greenville Health System Cancer Institute-Andrews Suspended
Greenville, South Carolina, United States, 29605
Greenville Health System Cancer Institute-Butternut Suspended
Greenville, South Carolina, United States, 29605
Greenville Health System Cancer Institute-Faris Recruiting
Greenville, South Carolina, United States, 29605
Contact: David L. Grisell    864-679-3966      
Principal Investigator: David L. Grisell         
Greenville Memorial Hospital Recruiting
Greenville, South Carolina, United States, 29605
Contact: David L. Grisell    864-679-3966      
Principal Investigator: David L. Grisell         
Saint Francis Cancer Center Recruiting
Greenville, South Carolina, United States, 29607
Contact: Robert D. Siegel    864-255-1713      
Principal Investigator: Robert D. Siegel         
Greenville Health System Cancer Institute-Eastside Recruiting
Greenville, South Carolina, United States, 29615
Contact: David L. Grisell    864-679-3966      
Principal Investigator: David L. Grisell         
Greenville Health System Cancer Institute-Greer Recruiting
Greer, South Carolina, United States, 29650
Contact: David L. Grisell    864-679-3966      
Principal Investigator: David L. Grisell         
Greenville Health System Cancer Institute-Seneca Recruiting
Seneca, South Carolina, United States, 29672
Contact: David L. Grisell    864-679-3966      
Principal Investigator: David L. Grisell         
Greenville Health System Cancer Institute-Spartanburg Recruiting
Spartanburg, South Carolina, United States, 29307
Contact: David L. Grisell    864-679-3966      
Principal Investigator: David L. Grisell         
United States, South Dakota
Sanford USD Medical Center - Sioux Falls Recruiting
Sioux Falls, South Dakota, United States, 57117-5134
Contact: Kayelyn J. Wagner    605-328-1367      
Principal Investigator: Kayelyn J. Wagner         
United States, Tennessee
T C Thompson Children's Hospital Recruiting
Chattanooga, Tennessee, United States, 37403
Contact: Manoo G. Bhakta       helpdesk@childrensoncologygroup.org   
Principal Investigator: Manoo G. Bhakta         
East Tennessee Childrens Hospital Suspended
Knoxville, Tennessee, United States, 37916
St. Jude Children's Research Hospital Recruiting
Memphis, Tennessee, United States, 38105
Contact: Wayne L. Furman       helpdesk@childrensoncologygroup.org   
Principal Investigator: Wayne L. Furman         
Vanderbilt University/Ingram Cancer Center Recruiting
Nashville, Tennessee, United States, 37232
Contact: Scott C. Borinstein    800-811-8480      
Principal Investigator: Scott C. Borinstein         
United States, Texas
Dell Children's Medical Center of Central Texas Recruiting
Austin, Texas, United States, 78723
Contact: Amy C. Fowler       helpdesk@childrensoncologygroup.org   
Principal Investigator: Amy C. Fowler         
Driscoll Children's Hospital Recruiting
Corpus Christi, Texas, United States, 78411
Contact: Nkechi I. Mba       helpdesk@childrensoncologygroup.org   
Principal Investigator: Nkechi I. Mba         
Medical City Dallas Hospital Recruiting
Dallas, Texas, United States, 75230
Contact: Stanton C. Goldman    972-566-5588      
Principal Investigator: Stanton C. Goldman         
Parkland Memorial Hospital Recruiting
Dallas, Texas, United States, 75235
Contact: Andrew A. Martin    214-648-7097      
Principal Investigator: Andrew A. Martin         
UT Southwestern/Simmons Cancer Center-Dallas Recruiting
Dallas, Texas, United States, 75390
Contact: Andrew A. Martin    214-648-7097      
Principal Investigator: Andrew A. Martin         
El Paso Children's Hospital Recruiting
El Paso, Texas, United States, 79905
Contact: Lisa L. Hartman       helpdesk@childrensoncologygroup.org   
Principal Investigator: Lisa L. Hartman         
Cook Children's Medical Center Recruiting
Fort Worth, Texas, United States, 76104
Contact: Karen H. Albritton    800-422-9567      
Principal Investigator: Karen H. Albritton         
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Mehmet F. Okcu    713-798-1354    burton@bcm.edu   
Principal Investigator: Mehmet F. Okcu         
M D Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Douglas J. Harrison    401-444-1488      
Principal Investigator: Douglas J. Harrison         
Covenant Children's Hospital Recruiting
Lubbock, Texas, United States, 79410
Contact: Kishor M. Bhende    806-775-8590      
Principal Investigator: Kishor M. Bhende         
University Medical Center Recruiting
Lubbock, Texas, United States, 79415
Contact: Mohamad M. Al-Rahawan    309-655-3258      
Principal Investigator: Mohamad M. Al-Rahawan         
Texas Tech University Health Sciences Center-Lubbock Recruiting
Lubbock, Texas, United States, 79430
Contact: Mohamad M. Al-Rahawan    309-655-3258      
Principal Investigator: Mohamad M. Al-Rahawan         
Children's Hospital of San Antonio Recruiting
San Antonio, Texas, United States, 78207
Contact: Timothy C. Griffin    800-248-1199      
Principal Investigator: Timothy C. Griffin         
Methodist Children's Hospital of South Texas Recruiting
San Antonio, Texas, United States, 78229
Contact: Vinod K. Gidvani-Diaz       helpdesk@childrensoncologygroup.org   
Principal Investigator: Vinod K. Gidvani-Diaz         
University of Texas Health Science Center at San Antonio Recruiting
San Antonio, Texas, United States, 78229
Contact: Anne-Marie R. Langevin    210-450-3800    CTO@uthscsa.edu   
Principal Investigator: Anne-Marie R. Langevin         
Scott and White Memorial Hospital Suspended
Temple, Texas, United States, 76508
United States, Utah
Huntsman Cancer Institute/University of Utah Suspended
Salt Lake City, Utah, United States, 84112
Primary Children's Hospital Recruiting
Salt Lake City, Utah, United States, 84113
Contact: Phillip E. Barnette       helpdesk@childrensoncologygroup.org   
Principal Investigator: Phillip E. Barnette         
South Jordan Health Center Suspended
South Jordan, Utah, United States, 84009
United States, Vermont
Central Vermont Medical Center/National Life Cancer Treatment Recruiting
Berlin, Vermont, United States, 05602
Contact: Alan C. Homans    802-656-8990      
Principal Investigator: Alan C. Homans         
University of Vermont Medical Center Recruiting
Burlington, Vermont, United States, 05401
Contact: Alan C. Homans    802-656-8990      
Principal Investigator: Alan C. Homans         
University of Vermont College of Medicine Recruiting
Burlington, Vermont, United States, 05405
Contact: Alan C. Homans    802-656-8990      
Principal Investigator: Alan C. Homans         
United States, Virginia
University of Virginia Cancer Center Recruiting
Charlottesville, Virginia, United States, 22908
Contact: William C. Petersen    434-243-6322    JME3D@hscmail.mcc.virginia.edu   
Principal Investigator: William C. Petersen         
Inova Fairfax Hospital Recruiting
Falls Church, Virginia, United States, 22042
Contact: Marshall A. Schorin    703-208-6650    Stephanie.VanBebber@inova.org   
Principal Investigator: Marshall A. Schorin         
Childrens Hospital-King's Daughters Recruiting
Norfolk, Virginia, United States, 23507
Contact: Eric J. Lowe       helpdesk@childrensoncologygroup.org   
Principal Investigator: Eric J. Lowe         
Virginia Commonwealth University/Massey Cancer Center Recruiting
Richmond, Virginia, United States, 23298
Contact: Gita V. Massey       helpdesk@childrensoncologygroup.org   
Principal Investigator: Gita V. Massey         
Carilion Clinic Children's Hospital Recruiting
Roanoke, Virginia, United States, 24014
Contact: Mandy M. Atkinson       helpdesk@childrensoncologygroup.org   
Principal Investigator: Mandy M. Atkinson         
United States, Washington
Providence Regional Cancer System-Aberdeen Suspended
Aberdeen, Washington, United States, 98520
PeaceHealth Saint Joseph Medical Center Suspended
Bellingham, Washington, United States, 98225
Providence Regional Cancer System-Centralia Suspended
Centralia, Washington, United States, 98531
Providence Regional Cancer Partnership Suspended
Everett, Washington, United States, 98201
Swedish Cancer Institute-Issaquah Suspended
Issaquah, Washington, United States, 98029
Kadlec Clinic Hematology and Oncology Recruiting
Kennewick, Washington, United States, 99336
Contact: Eugenia Chang    888-823-5923    ctsucontact@westat.com   
Principal Investigator: Eugenia Chang         
Providence Regional Cancer System-Lacey Suspended
Lacey, Washington, United States, 98503
PeaceHealth Saint John Medical Center Suspended
Longview, Washington, United States, 98632
Seattle Children's Hospital Recruiting
Seattle, Washington, United States, 98105
Contact: Douglas S. Hawkins       helpdesk@childrensoncologygroup.org   
Principal Investigator: Douglas S. Hawkins         
Swedish Medical Center-Ballard Campus Suspended
Seattle, Washington, United States, 98107
Kaiser Permanente Washington Suspended
Seattle, Washington, United States, 98112
Swedish Medical Center-First Hill Suspended
Seattle, Washington, United States, 98122-4307
Providence Sacred Heart Medical Center and Children's Hospital Recruiting
Spokane, Washington, United States, 99204
Contact: Judy L. Felgenhauer       helpdesk@childrensoncologygroup.org   
Principal Investigator: Judy L. Felgenhauer         
Madigan Army Medical Center Recruiting
Tacoma, Washington, United States, 98431
Contact: Melissa A. Forouhar    301-319-2100      
Principal Investigator: Melissa A. Forouhar         
PeaceHealth Southwest Medical Center Suspended
Vancouver, Washington, United States, 98664
Providence Saint Mary Regional Cancer Center Suspended
Walla Walla, Washington, United States, 99362
North Star Lodge Cancer Center at Yakima Valley Memorial Hospital Suspended
Yakima, Washington, United States, 98902
United States, West Virginia
West Virginia University Charleston Recruiting
Charleston, West Virginia, United States, 25304
Contact: Ashley E. Meyer    304-388-9944      
Principal Investigator: Ashley E. Meyer         
West Virginia University Healthcare Recruiting
Morgantown, West Virginia, United States, 26506
Contact: Stephan R. Paul    304-293-7374    cancertrialsinfo@hsc.wvu.edu   
Principal Investigator: Stephan R. Paul         
United States, Wisconsin
Aurora Cancer Care-Southern Lakes VLCC Suspended
Burlington, Wisconsin, United States, 53105
Aurora Health Center-Fond du Lac Suspended
Fond Du Lac, Wisconsin, United States, 54937
Aurora Health Care Germantown Health Center Suspended
Germantown, Wisconsin, United States, 53022
Aurora Cancer Care-Grafton Suspended
Grafton, Wisconsin, United States, 53024
Aurora BayCare Medical Center Suspended
Green Bay, Wisconsin, United States, 54311
Aurora Cancer Care-Kenosha South Suspended
Kenosha, Wisconsin, United States, 53142
University of Wisconsin Hospital and Clinics Recruiting
Madison, Wisconsin, United States, 53792
Contact: Kenneth B. De Santes    800-622-8922      
Principal Investigator: Kenneth B. De Santes         
Vince Lombardi Cancer Clinic-Marinette Suspended
Marinette, Wisconsin, United States, 54143
Marshfield Clinic Recruiting
Marshfield, Wisconsin, United States, 54449
Contact: Michael J. McManus    715-389-4457      
Principal Investigator: Michael J. McManus         
Aurora Cancer Care-Milwaukee Suspended
Milwaukee, Wisconsin, United States, 53209
Aurora Saint Luke's Medical Center Suspended
Milwaukee, Wisconsin, United States, 53215
Children's Hospital of Wisconsin Recruiting
Milwaukee, Wisconsin, United States, 53226
Contact: Meghen B. Browning    414-805-4380      
Principal Investigator: Meghen B. Browning         
Froedtert and the Medical College of Wisconsin Recruiting
Milwaukee, Wisconsin, United States, 53226
Contact: John A. Charlson    414-805-4380      
Principal Investigator: John A. Charlson         
Aurora Sinai Medical Center Suspended
Milwaukee, Wisconsin, United States, 53233
Vince Lombardi Cancer Clinic - Oshkosh Suspended
Oshkosh, Wisconsin, United States, 54904
Aurora Cancer Care-Racine Suspended
Racine, Wisconsin, United States, 53406
Vince Lombardi Cancer Clinic-Sheboygan Suspended
Sheboygan, Wisconsin, United States, 53081
Aurora Medical Center in Summit Suspended
Summit, Wisconsin, United States, 53066
Vince Lombardi Cancer Clinic-Two Rivers Suspended
Two Rivers, Wisconsin, United States, 54241
Aurora Cancer Care-Waukesha Suspended
Waukesha, Wisconsin, United States, 53188
Aurora Cancer Care-Milwaukee West Suspended
Wauwatosa, Wisconsin, United States, 53226
Aurora West Allis Medical Center Suspended
West Allis, Wisconsin, United States, 53227
Canada, Alberta
Cross Cancer Institute Suspended
Edmonton, Alberta, Canada, T6G 1Z2
Canada, British Columbia
British Columbia Children's Hospital Suspended
Vancouver, British Columbia, Canada, V6H 3V4
Canada, Manitoba
CancerCare Manitoba Recruiting
Winnipeg, Manitoba, Canada, R3E 0V9
Contact: Shantanu Banerji    866-561-1026    CIO_Web@cancercare.mb.ca   
Principal Investigator: Shantanu Banerji         
Canada, Newfoundland and Labrador
Janeway Child Health Centre Recruiting
Saint John's, Newfoundland and Labrador, Canada, A1B 3V6
Contact: Lisa Anne B. Goodyear    866-722-1126      
Principal Investigator: Lisa Anne B. Goodyear         
Canada, Nova Scotia
IWK Health Centre Recruiting
Halifax, Nova Scotia, Canada, B3K 6R8
Contact: Conrad V. Fernandez    902-470-8394      
Principal Investigator: Conrad V. Fernandez         
Canada, Ontario
McMaster Children's Hospital at Hamilton Health Sciences Suspended
Hamilton, Ontario, Canada, L8N 3Z5
Children's Hospital Suspended
London, Ontario, Canada, N6A 5W9
Hospital for Sick Children Suspended
Toronto, Ontario, Canada, M5G 1X8
Canada, Quebec
CIUSSSEMTL-Hopital Maisonneuve-Rosemont Suspended
Montreal, Quebec, Canada, H1T 2M4
CHUM - Hopital Notre-Dame Suspended
Montreal, Quebec, Canada, H2L 4M1
The Montreal Children's Hospital of the MUHC Recruiting
Montreal, Quebec, Canada, H3H 1P3
Contact: Sharon B. Abish       helpdesk@childrensoncologygroup.org   
Principal Investigator: Sharon B. Abish         
Centre Hospitalier Universitaire Sainte-Justine Suspended
Montreal, Quebec, Canada, H3T 1C5
Canada, Saskatchewan
Allan Blair Cancer Centre Recruiting
Regina, Saskatchewan, Canada, S4T 7T1
Contact: Muhammad Salim    306-766-2213      
Principal Investigator: Muhammad Salim         
Canada
Centre Hospitalier Universitaire de Quebec Recruiting
Quebec, Canada, G1V 4G2
Contact: Bruno Michon       helpdesk@childrensoncologygroup.org   
Principal Investigator: Bruno Michon         
Puerto Rico
San Jorge Children's Hospital Recruiting
San Juan, Puerto Rico, 00912
Contact: Luis A. Clavell       helpdesk@childrensoncologygroup.org   
Principal Investigator: Luis A. Clavell         
University Pediatric Hospital Recruiting
San Juan, Puerto Rico, 00926
Contact: Luis A. Clavell       helpdesk@childrensoncologygroup.org   
Principal Investigator: Luis A. Clavell         
Sponsors and Collaborators
National Cancer Institute (NCI)
Investigators
Principal Investigator: Aaron Weiss Children's Oncology Group
  More Information

Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT02180867     History of Changes
Other Study ID Numbers: NCI-2014-01340
NCI-2014-01340 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
s14-02023
ARST1321
ARST1321 ( Other Identifier: Childrens Oncology Group )
ARST1321 ( Other Identifier: CTEP )
U10CA180830 ( U.S. NIH Grant/Contract )
U10CA180886 ( U.S. NIH Grant/Contract )
U10CA098543 ( U.S. NIH Grant/Contract )
First Submitted: July 1, 2014
First Posted: July 3, 2014
Last Update Posted: November 21, 2017
Last Verified: November 2017

Additional relevant MeSH terms:
Neoplasms
Sarcoma
Osteosarcoma
Leiomyosarcoma
Liposarcoma
Chondrosarcoma
Sarcoma, Synovial
Fibrosarcoma
Nerve Sheath Neoplasms
Neurofibroma
Histiocytoma
Sarcoma, Alveolar Soft Part
Neurilemmoma
Neurofibrosarcoma
Histiocytoma, Benign Fibrous
Sarcoma, Clear Cell
Granuloma, Plasma Cell
Chondrosarcoma, Mesenchymal
Histiocytoma, Malignant Fibrous
Skin Neoplasms
Granular Cell Tumor
Glomus Tumor
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms, Bone Tissue
Neoplasms, Connective Tissue
Neoplasms, Muscle Tissue
Neoplasms, Adipose Tissue
Neoplasms, Fibrous Tissue
Neoplasms, Nerve Tissue